08/16/2011

RMS Medical Products

RMS subcutaneous needle sets being shown at MEDICA

RMS Subcutaneous Needle Sets will be exhibited at the 2011 Medica. The needle sets are intended for the delivery of medication to subcutaneous tissue.

Andrew I. Sealfon, president of the company, which based in Chester, NY, USA, said, “Although we use a needle which is smaller in gauge than many needles being used for subcutaneous administration of certain drugs, our design results in flow rates comparable to, or better than, the flow rates of the larger needles. This can result in less pain and discomfort for the patient, less insertion difficulty for medical personnel, and shorter infusion times.”

The needle sets are an ideal companion for RMS Medical Products’ FREEDOM60 Syringe Infusion System, which has enhanced the lifestyle of numerous patients requiring regular drug infusions due to its portability and ease of use. FREEDOM60 enjoys widespread use by ambulatory patients at home as well as those in healthcare facilities. “Even though the RMS Subcutaneous Needle Sets provide advanced fluidics, the pricing is highly competitive, just as FREEDOM60 has been in the infusion pump market” Sealfon said.

The RMS Subcutaneous Needle Sets use 26 gauge needles, which have a smaller outside diameter than commonly used 24 gauge needles. This translates into less “ouch” when the needles are inserted, greater comfort throughout lengthy infusions, and faster flow rates. When used in multi-needle sets, as typically is the case for subcutaneous immune globulin infusions, the RMS Subcutaneous Needle Sets distribute equal volumes of drug to all needles. The sets are available in single, double, triple and quad configurations. RMS produces a low residual “Y” connector which allows up to 8 needles to be used for a single infusion. Needles are available in 6mm, 9mm and 12mm lengths.

“We believe that patients who are fearful of needles and uncomfortable with the thought of having to undergo lengthy infusions will appreciate the new needle sets,” Sealfon concluded.